Welcome to our dedicated page for Arbutus Biopharma Corporation news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharma Corporation stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (cHBV). Utilizing its extensive expertise in virology, Arbutus focuses on developing a portfolio of drug candidates with multiple mechanisms of action aimed at curing Hepatitis B virus (HBV) disease. The company's lead RNA interference (RNAi) therapeutic, imdusiran (AB-729), targets HBV proteins to reduce viral antigens and reawaken the host's immune response. Imdusiran is currently undergoing multiple Phase 2a clinical trials, demonstrating promising results in reducing hepatitis B surface antigen (HBsAg) levels and achieving functional cures in a subset of patients.
Arbutus leverages its proprietary lipid nanoparticle (LNP) technology and expertise in RNAi therapeutics to develop innovative treatments. Beyond HBV, the company has a robust pipeline that includes AB-101, an oral PD-L1 inhibitor, currently in Phase 1a/1b trials. This compound aims to enable controlled checkpoint blockade while minimizing systemic safety issues.
Recent clinical data highlight the potential of Arbutus' combination therapies. In the IM-PROVE I trial, imdusiran combined with pegylated interferon alfa-2a (IFN) and nucleos(t)ide analogue (NA) therapy demonstrated sustained HBsAg loss in some patients, suggesting a path toward a functional cure. Another study, IM-PROVE II, showed that combining imdusiran with VTP-300, an immunotherapeutic, resulted in meaningful reductions in HBsAg levels and the discontinuation of NA therapy in a significant number of patients.
Financially, Arbutus maintains a strong position with a cash runway extending into the first quarter of 2026. They are actively involved in ongoing patent litigation to protect their LNP technology, seeking fair compensation for its use in mRNA COVID-19 vaccines by Moderna and Pfizer/BioNTech.
Arbutus continues to engage in strategic collaborations and partnerships to advance its mission of curing HBV and other chronic infectious diseases. For more detailed information, visit www.arbutusbio.com.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its Q3 2021 financial results, highlighting key developments in its hepatitis B virus (HBV) treatment pipeline. The company has initiated a Phase 2a trial combining AB-729 with standard NA therapy and Peg-IFNα-2a, aiming for multiple data readouts in Q4 2021. Financially, Arbutus reported a net loss of $24.2 million, a slight increase from $21.8 million year-over-year. The company also extended its cash runway into Q2 2023, with $151.9 million in cash on hand as of September 30, 2021, amidst rising R&D expenses.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the presentation of data on its GalNAc-siRNA, AB-729, at The Liver Meeting® 2021, occurring from November 12-15, 2021. The poster, titled "Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729," indicates that AB-729 is generally safe and demonstrates sustained HBsAg decline in chronic hepatitis B patients. Key findings show maintained HBsAg suppression in some patients for up to 20 weeks post-treatment.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its schedule for the Q3 2021 financial results and corporate update on November 4, 2021. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the live webcast via the company's website. Arbutus is focused on developing treatments for chronic hepatitis B and coronaviruses, leveraging a diverse portfolio of assets.
Arbutus Biopharma Corporation (Nasdaq: ABUS) focuses on innovative therapies to combat chronic hepatitis B virus (HBV) infections and coronaviruses, including COVID-19. On September 28, 2021, the company announced participation in two key virtual investor conferences in October. The first is Chardan's 5th Annual Genetic Medicines Conference on October 4-5, featuring a fireside chat on October 5 at 4:30 PM ET. The second is the H.C. Wainwright HBV Virtual Conference on October 13, with a fireside chat at 1:00 PM ET. Webcast links are available on Arbutus' website, along with archived replays.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the appointment of Lisa M. Caperelli as Vice President of Investor Relations, a newly created role. Caperelli, with 20 years of experience in investor relations within the biotech sector, will head strategy and communications reporting to CFO David Hastings. This change aims to enhance engagement with the investment community regarding Arbutus’ efforts in providing a functional cure for chronic hepatitis B and ongoing coronavirus therapies. Caperelli previously held roles at various biotech companies, including Harmony Biosciences.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its participation in two upcoming virtual investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, featuring a fireside chat on September 13 at 7:00 am ET. The second is the Cantor Global Healthcare Conference from September 27-30, 2021, with a formal presentation on September 30 at 8:40 am ET. Presenters include the company's CEO and scientific leaders. Webcast links for both events are available via Arbutus' website.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced significant advancements in its hepatitis B virus (HBV) pipeline, particularly AB-729, showcased in four abstracts at the EASL International Liver Congress™. The drug received FDA authorization for a Phase 2a trial, focusing on safety and antiviral activity when combined with nucleos(t)ide analog therapy. The press release highlighted two new collaborations to evaluate AB-729’s combination potential. Financially, Arbutus reported a net loss of $22.7 million for Q2 2021, with cash reserves of $121.3 million, sufficient for operations into Q3 2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 4:05 PM ET. The fireside chat will feature key executives, including President and CEO William Collier and Chief Scientific Officer Dr. Michael Sofia. A live webcast will be accessible via the Investors section of Arbutus' website, with an archive available post-conference. The company focuses on developing a cure for chronic hepatitis B virus (HBV) and therapies for coronaviruses, including COVID-19.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its plans to release its second quarter 2021 financial results on August 5, 2021, at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. The company focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses, including COVID-19. A live webcast will be accessible on their website, and an archived version will be available post-event. Investors can dial in using designated numbers for domestic and international participants.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has received FDA authorization for its Investigational New Drug application to initiate a Phase 2a clinical trial for AB-729, targeting chronic hepatitis B virus (CHB) infection. The trial will evaluate the safety and efficacy of AB-729 in combination with nucleos(t)ide analog therapy and short courses of Peg-IFNα-2a. The randomized trial aims to enroll 40 subjects and is expected to start this quarter, with the potential to establish AB-729 as a cornerstone therapy for CHB.
FAQ
What is the current stock price of Arbutus Biopharma Corporation (ABUS)?
What is the market cap of Arbutus Biopharma Corporation (ABUS)?
What is Arbutus Biopharma's primary focus?
What is imdusiran (AB-729)?
What are the key recent achievements of Arbutus Biopharma?
What is the status of Arbutus' financial condition?
What technologies does Arbutus leverage for its treatments?
What are the current projects Arbutus Biopharma is working on?
Has Arbutus formed any strategic partnerships?
What is the significance of Arbutus' patent litigation?
How successful have Arbutus' clinical trials been?
Where can more information about Arbutus Biopharma be found?
